S&P 500
7,633.20
+0.31%
Dow Jones
53,893.00
+1.14%
Nasdaq 100
29,106.20
+0.99%
Russell 2000
2,995.41
+0.37%
FTSE 100
10,904.40
+0.20%
Nikkei 225
64,309.90
+1.28%
McKesson

McKesson (MCK) Q1 2027 Earnings

Reported Aug 5, 2026 at 4:06 PM ET · SEC Source

Q1 27 EPS Adjusted

$9.93

BEAT +4.14%

Est. $9.54

Q1 27 Revenue

$105.38B

BEAT +1.58%

Est. $103.74B

vs S&P Since Q1 27

+4.1%

BEATING MARKET

MCK +4.7% vs S&P +0.6%

Market Reaction

Did MCK Beat Earnings? Q1 2027 Results

McKesson delivered a broad-based beat in its fiscal first quarter of 2027, with adjusted EPS of $9.93 clearing the $9.54 consensus estimate by 4.14% and revenue of $105.38 billion topping expectations by 1.58% on 7.7% year-over-year growth, extending… Read more McKesson delivered a broad-based beat in its fiscal first quarter of 2027, with adjusted EPS of $9.93 clearing the $9.54 consensus estimate by 4.14% and revenue of $105.38 billion topping expectations by 1.58% on 7.7% year-over-year growth, extending the company's streak of beating consensus EPS estimates to four consecutive quarters. The standout driver was the Oncology & Multispecialty segment, which posted 33% revenue growth to $14.22 billion and 41% adjusted operating profit growth to $405.00 million, while North American Pharmaceutical revenues climbed to $86.77 billion with adjusted operating profit rising 19% to $894.00 million on specialty distribution strength. Notably, analysts heading into the print had flagged uncertainty around revenue consistency after a prior-quarter miss, making the clean top- and bottom-line beat all the more meaningful. Looking ahead, McKesson raised its full-year fiscal 2027 adjusted EPS guidance to $44.20 to $45.00, reflecting 13% to 15% growth versus the prior year, as management cited sustained operational momentum across its core distribution businesses.

Key Takeaways

  • • Increased prescription transaction volumes, including higher specialty product volumes
  • • Growth in distribution of specialty products to health systems and strategic accounts
  • • Timing of new product launches benefiting North American Pharmaceutical
  • • Growth in provider solutions and specialty distribution in Oncology & Multispecialty, including acquisition contributions
  • • Higher demand for access solutions in Prescription Technology Solutions
  • • Lower share count from aggressive share repurchase program
  • • Lower contributions from branded pharmaceuticals partially offset revenue growth

MCK Forward Guidance & Outlook

McKesson raised its fiscal 2027 full-year Adjusted Earnings per Diluted Share guidance to $44.20–$45.00 from the previous range of $43.80–$44.60, indicating 13%–15% growth compared to the prior year. The raise reflects strong first quarter performance and sustainable operational momentum. The company does not provide forward-looking guidance on a GAAP basis. Additional modeling considerations will be provided in the earnings call presentation.

24/7 Wall St

MCK YoY Financials

Q1 2027 vs Q1 2026, source: SEC Filings

24/7 Wall St

MCK Revenue by Segment

With YoY comparisons, source: SEC Filings

Q1 26 Q1 27

“McKesson delivered a strong start to fiscal 2027, underscored by momentum across the enterprise and disciplined execution against our strategic priorities. Our first quarter performance exceeded our expectations, highlighted by 20% growth in Adjusted Earnings per Diluted Share. It demonstrates the strength of our core distribution businesses, continued growth in oncology and multispecialty, and solid execution across our biopharma services platform.”

— Brian Tyler, Q1 2027 Earnings Press Release

Back to MCK Stock Page